Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

NCT07209813 is registered in ClinicalTrials.gov with Beijing Gene Key Life Technology Co., Ltd as lead sponsor.

NCT NCT07209813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07209813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
Beijing Gene Key Life Technology Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2025
Completion date
October 31, 2027
Enrollment
48 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc), unresectable hepatocellular cancer